Thomas P. Cirrito

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY.

Antegrin Therapeutics LLC develops novel therapies for fibrotic diseases. It focuses on idiopathic pulmonary fibrotic diseases, which are conditions that involve out-of-control scarring of organs. The company was founded by David Griggs and Peter Ruminski in 2012 and is headquartered in St. Louis, MO.

Indalo Therapeutics, Inc. operates as a biopharmaceutical firm that develops integrin antagonists for patients suffering from serious fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). The company was founded by David Griggs, Williamson Z. Bradford III, Peter Ruminski, and Robert W. Karr and is headquartered in Cambridge, MA.

Biotagenics, Inc. develops novel therapeutics and diagnostics. The company is based in Toronto, Canada. The Canadian company was founded by Thomas P. Cirrito, Ali Riazi, Daniel Figeys, Alain Stintzi. Thomas P. Cirrito has been the CEO since incorporation.

Filament BioSolutions, Inc. develops medical and functional foods for diseases. The company is based in Long Island City, NY. The company was founded by Thomas P. Cirrito. Thomas P. Cirrito has been the CEO since incorporation.

Immunovent LLC is a biotech company based in New York, NY. Immunovent is revolutionizing allergy diagnostics by coupling existing clinical practices with their patented lamb-dx test. The lamb-dx test detects small amounts of antigen-specific ige from symptomatic areas of the body, such as the mouth and the nose, through a gentle and easy mucosal brush sampling procedure and a proprietary diagnostic assay. This allows for the rapid and safe diagnosis of common allergies without the inconveniences and issues of conventional skin prick and blood testing. The private company was founded by Kate Rochlin and Thomas P. Cirrito. Thomas P. Cirrito has been the CEO since incorporation.

Agelity Biomechanics, Inc. is a private company based in New York that specializes in developing innovative technologies to improve human movement and mobility. Agelity Biomechanics is committed to advancing the field of biomechanics and helping people move better and live healthier lives. The American company was founded by Russell F. Warren and Suzanne Maher, and Dennis W. O'Dowd has been the CEO of the company since 2018.